Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pregnancy, Preeclampsia (PE)
Interventions: 17 OHPC; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension
Interventions: Telehealth, Educational materials; Behavioral
Lead sponsor: LeadingAge; Other
Eligibility: 55 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Bellefontaine, Ohio • Miamisburg, Ohio • Spring Valley, Ohio + 1 more

Conditions: Hypertension
Interventions: PS433540, placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more

Conditions: Heart Diseases, Hypertension, Pulmonary
Interventions: tezosentan, placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Stanford, California • New York, New York • Durham, North Carolina + 5 more

Conditions: Hypertension
Interventions: Telemedicine management of Hypertension, Usual Care; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes, Kidney Disease, Hypertension
Interventions: losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Placebo, IONIS-AGT-LRx; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 44 more

Conditions: Hypertension, Diabetes, Postpartum, Pregnancy, Anxiety, Depression, Obesity
Interventions: Facilitated Transition to Primary Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Hypertension
Interventions: Self-Management / MTM using Health IT; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions: Orlistat, Placebo; Drug
Lead sponsor: Jack Yanovski; NIH
Eligibility: 12 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prehypertension
Interventions: Marealis refined peptide concentrate, Placebo; Dietary Supplement
Lead sponsor: KGK Science Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: High Blood Pressure
Interventions: Control Condition, Regret Lottery; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV/AIDS, Hypertension, Hyperlipidemias
Interventions: Multi-component intervention, General prevention education; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Durham, North Carolina • Cleveland, Ohio

Conditions: Glaucoma Open-angle
Interventions: Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Hypertension
Interventions: Motivational interviewing (MINT-TLC); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Geno LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more

Conditions: End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
Interventions: Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Matching Placebo, IW-1973; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Insufficient Sleep, Hypertension
Interventions: Intervention; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 13 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 51
States / cities: La Jolla, California • Los Angeles, California • Pasadena, California + 45 more

Conditions: Hypertension
Interventions: High Intensity Interval Training (HIIT) Exercise; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: High Blood Pressure
Interventions: Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Initial Evaluation of Telehealth Blood Pressure Stations in Nutrition Centers

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Tailoring TM-HTN Intervention for Black Patients

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions

Self-Management in Stroke Survivors

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

Behavioral Economics Trial To Enhance Regulation of Blood Pressure (BETTER-BP)

A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Faith-based Approaches in the Treatment of Hypertension (FAITH)

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Sleep Promotion and Pediatric Hypertension

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Improving Age-Related Cognitive Decline With Exercise in Hypertensive Older Adults

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function